drugset / Trial / NCT01954992
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
Timeline
- Start
- 2014-04
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glufosfamide | Small molecule | 4500 mg/m2 | Intravenous |
| Comparator | fluorouracil | Small molecule | 600 mg/m2 | Intravenous |